Evidence map›Paper›PMID 41309546›Full record

ArticleBlood cancer journal2025

CDK9 is a dependency in GATA-3 driven and MCL-1 independent T-cell Lymphomas.

Chenguang Wang, Suhaib Abdelrahman, Xiangrong Geng, Alyssa Burgess, Ying S Hu, Mohd Ahmar Rauf, Nermin Kady, Yao Fu, Tara A Reilly, Ira P Maine and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Chenguang Wang *Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA. wchengua@med.umich.edu.ORCID 0000-0002-9082-2117
Suhaib Abdelrahman *Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.
Xiangrong Geng *Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-0682-5236
Alyssa BurgessDepartment of Chemistry, College of Liberal Arts and Sciences, University of Illinois Chicago, Chicago, IL, USA.
Ying S HuDepartment of Chemistry, College of Liberal Arts and Sciences, University of Illinois Chicago, Chicago, IL, USA.
Mohd Ahmar RaufDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.
Nermin KadyDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.
Yao FuDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.
Tara A ReillyDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.
Ira P MaineDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.
Phillip BoonstraDepartment of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA.
Kirill SabitovDepartment of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA.ORCID 0009-0004-9457-7587
Carlos Murga-ZamalloaDepartment of Pathology, University of Illinois Chicago, Chicago, IL, USA.ORCID 0000-0002-2238-5066
Ryan A WilcoxDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA. rywilcox@med.umich.edu.ORCID 0000-0002-6420-0760

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
Pacritinib in rel/refr T-cell lymphomasR01CA265929 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WILCOX, RYAN A · 2021 to 2025
$3.2M
WASp signaling in T-cell lymphomasR01CA293380 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Carlos A. Murga-Zamalloa · 2024 to 2026
$2.5M
THE T-CELL RECEPTOR'S ROLE IN T-CELL LYMPHOMA PATHOGENESISR37CA233476 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WILCOX, RYAN A · 2019 to 2025
$2.2M
Ultrasensitive quantification of cytokine release from T cellsR35GM146786 · NIGMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Ying Samuel Hu · 2022 to 2026
$2.2M
Notch and GATA-3 as novel therapeutic targets in T-cell lymphomasR01CA236722 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WILCOX, RYAN A · 2020 to 2024
$1.8M
NCI NIH HHS P30 CA046592NCI NIH HHS R01 CA236722NCI NIH HHS R01 CA265929NCI NIH HHS R01 CA293380NCI NIH HHS R37 CA233476NIGMS NIH HHS R35 GM146786U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA236722U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA265929U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R37CA233476
6 · The paper itself

Abstract

The transcription factor GATA-binding protein 3 (GATA-3) regulates oncogenic transcriptional programs across diverse T-cell lymphomas, including subsets of both peripheral and primary cutaneous T-cell lymphomas. These GATA-3 dependent transcriptional programs, in collaboration with the genetic landscape, promote cell growth and survival, and confer resistance to conventional chemotherapeutic agents. We observed that transcriptional cyclin dependent kinase 9 (CDK9) activation regulates diverse oncogenic transcriptional programs in these aggressive T-cell lymphomas and is thus a novel therapeutic vulnerability. Using complementary and orthogonal approaches, we identified multiple independent mechanisms by which CDK9 promotes T-cell lymphomagenesis, including a mechanism by which GATA-3 promotes CDK9 activation at GATA-3 dependent loci. We also identify novel mechanisms by which GATA-3 and CDK9 regulate rRNA transcription and processing, respectively, collaboratively promoting ribosome biogenesis. Therefore, CDK9 is a therapeutic vulnerability across genetically and transcriptionally diverse T-cell lymphomas, including those for which GATA-3 is oncogenic.

Indexed as

Cyclin-Dependent Kinase 9GATA3 Transcription FactorLymphoma, T-CellMyeloid Cell Leukemia Sequence 1 ProteinAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceCDK9 protein, humanCyclin-Dependent Kinase 9GATA3 protein, humanGATA3 Transcription FactorMCL1 protein, humanMyeloid Cell Leukemia Sequence 1 Protein

Identifiers

PMID41309546
PMCPMC12783670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.